HomeDMN • FRA
add
Diamyd Medical AB
Previous close
€1.41
Day range
€1.29 - €1.29
Year range
€0.65 - €1.80
Market cap
1.80B SEK
Avg Volume
914.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Financials
Income Statement
Revenue
Net income
| (SEK) | Feb 2026info | Y/Y change |
|---|---|---|
Revenue | 962.00K | 1,018.60% |
Operating expense | 65.20M | 45.88% |
Net income | -62.88M | -40.14% |
Net profit margin | -6.54K | 87.47% |
Earnings per share | — | — |
EBITDA | -63.24M | -43.70% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Feb 2026info | Y/Y change |
|---|---|---|
Cash and short-term investments | 190.73M | 83.83% |
Total assets | 253.63M | 40.22% |
Total liabilities | 83.84M | 20.89% |
Total equity | 169.80M | — |
Shares outstanding | — | — |
Price to book | — | — |
Return on assets | -58.47% | — |
Return on capital | -80.99% | — |
Cash Flow
Net change in cash
| (SEK) | Feb 2026info | Y/Y change |
|---|---|---|
Net income | -62.88M | -40.14% |
Cash from operations | -39.51M | 18.40% |
Cash from investing | -20.11M | -4,291.05% |
Cash from financing | -2.14M | -237.01% |
Net change in cash | -62.39M | -27.00% |
Free cash flow | -19.53M | 40.32% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
41
